Karyopharm Therapeutics Ownership | Who Owns Karyopharm Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Karyopharm Therapeutics Ownership Summary


Karyopharm Therapeutics is owned by 81.50% institutional investors, 4.46% insiders, and 14.04% retail investors. Commodore capital lp is the largest institutional shareholder, holding 17.83% of KPTI shares. T. Rowe Price Small-Cap Value is the top mutual fund, with 3.89% of its assets in Karyopharm Therapeutics shares.

KPTI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockKaryopharm Therapeutics81.50%4.46%14.04%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Commodore capital lp1.95M17.83%$10.86M
Ra capital management1.92M17.53%$10.68M
Adage capital partners gp1.81M16.52%$10.06M
T. rowe price investment management1.54M14.10%$8.59M
Goldman sachs group947.58K8.67%$5.28M
Catalio capital management, lp897.71K8.21%$5.00M
Ikarian capital733.43K6.71%$4.09M
Vanguard group559.62K6.46%$4.12M
Affinity asset advisors500.00K4.57%$2.79M
Avidity partners management lp463.74K4.24%$3.85M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Catalio capital management, lp897.71K1.04%$5.00M
Avidity partners management lp463.74K0.87%$3.85M
Commodore capital lp1.95M0.63%$10.86M
Acorn capital advisors287.83K0.46%$1.60M
Ikarian capital733.43K0.33%$4.09M
Birchview capital, lp419.83K0.23%$283.93K
Boxer capital management302.54K0.22%$1.69M
Affinity asset advisors500.00K0.14%$2.79M
Ra capital management1.92M0.11%$10.68M
Soleus capital management440.00K0.10%$2.45M

Top Buyers

HolderShares% AssetsChange
Commodore capital lp1.95M0.63%1.95M
Ra capital management1.92M0.11%1.92M
Adage capital partners gp1.81M0.02%1.39M
Goldman sachs group947.58K0.00%947.58K
Catalio capital management, lp897.71K1.04%754.73K

Top Sellers

HolderShares% AssetsChange
Blackrock4.17M0.00%-5.28M
Deutsche bank ag\---1.27M
Kennedy capital management---1.20M
Alphacentric advisors---1.13M
Opaleye management---930.00K

New Positions

HolderShares% AssetsChangeValue
Commodore capital lp1.95M0.63%1.95M$10.86M
Ra capital management1.92M0.11%1.92M$10.68M
Millennium management420.57K0.00%420.57K$2.34M
Acorn capital advisors287.83K0.46%287.83K$1.60M
Eversept partners, lp276.17K0.08%276.17K$1.54M

Sold Out

HolderChange
Pittenger & anderson-3.00
Zurcher kantonalbank (zurich cantonalbank)-6.00
Farther finance advisors-13.00
Nelson, van denburg & campbell wealth management group-22.00
Bruce g. allen investments-22.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202665-14.47%8,911,554-5.86%812.94%40-13.04%6-
Dec 31, 202512-79.31%752,172-74.49%80.74%5-72.22%--100.00%
Sep 30, 202518-62.50%552,924-86.33%60.29%5-79.17%3-50.00%
Jun 30, 2025524.00%4,384,528-15.32%50281.78%27575.00%7-83.33%
Mar 31, 202551-45.74%5,312,129-91.28%40.17%4-88.89%4386.96%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
T. Rowe Price Small-Cap Value876.50K3.89%18.71K
T. Rowe Price U.S. SC Value Eq Tr-D611.05K2.71%25.74K
Vanguard US Total Market Shares ETF3.42M2.71%-1.00
Vanguard Total Stock Mkt Idx Inv509.13K2.26%-
Vanguard Explorer Inv133.88K1.55%-
Vanguard Institutional Extnd Mkt Idx Tr215.08K0.95%-
AlphaCentric LifeSci Healthcare I1.13M0.90%-
AlphaCentric Life Sciences & Hlthcare I1.13M0.89%-
Kennedy Micro Cap1.03M0.81%-22.77K
T. Rowe Price U.S. SC Value Eq Tr-Z50.09K0.60%50.09K

Recent Insider Transactions


DateNameRoleActivityValue
May 14, 2026Poulton Stuart EVP, Chief Development OfficerSell$3.83K
May 14, 2026Rangwala Reshma EVP & Chief Medical OfficerSell$3.88K
May 14, 2026Cheng Sohanya Roshan EVP & Chief Commercial OfficerSell$3.08K
May 14, 2026Abate Kristin Chief Accounting OfficerSell$503.50
May 14, 2026Paulson Richard A. President and CEOSell$20.93K

Insider Transactions Trends


DateBuySell
2026 Q2-7
2026 Q1-9
2025 Q4-1
2025 Q3-9
2025 Q2-3

KPTI Ownership FAQ


Who Owns Karyopharm Therapeutics?

Karyopharm Therapeutics shareholders are primarily institutional investors at 81.50%, followed by 4.46% insiders and 14.04% retail investors. The average institutional ownership in Karyopharm Therapeutics's industry, Biotech Stocks , is 35.75%, which Karyopharm Therapeutics exceeds.

Who owns the most shares of Karyopharm Therapeutics?

Karyopharm Therapeutics’s largest shareholders are Commodore capital lp (1.95M shares, 17.83%), Ra capital management (1.92M shares, 17.53%), and Adage capital partners gp (1.81M shares, 16.52%). Together, they hold 51.89% of Karyopharm Therapeutics’s total shares outstanding.

Does Blackrock own Karyopharm Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Karyopharm Therapeutics.

Who is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested?

Catalio capital management, lp is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.04% of its assets in 897.71K Karyopharm Therapeutics shares, valued at 5M$.

Who is the top mutual fund holder of Karyopharm Therapeutics shares?

T. Rowe Price Small-Cap Value is the top mutual fund holder of Karyopharm Therapeutics shares, with 3.89% of its total shares outstanding invested in 876.5K Karyopharm Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools